JP2020536107A5 - - Google Patents

Download PDF

Info

Publication number
JP2020536107A5
JP2020536107A5 JP2020519400A JP2020519400A JP2020536107A5 JP 2020536107 A5 JP2020536107 A5 JP 2020536107A5 JP 2020519400 A JP2020519400 A JP 2020519400A JP 2020519400 A JP2020519400 A JP 2020519400A JP 2020536107 A5 JP2020536107 A5 JP 2020536107A5
Authority
JP
Japan
Prior art keywords
vaccine composition
composition according
dengue
administered
vaccination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020519400A
Other languages
English (en)
Japanese (ja)
Other versions
JP7313345B2 (ja
JP2020536107A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2018/001219 external-priority patent/WO2019069130A1/en
Publication of JP2020536107A publication Critical patent/JP2020536107A/ja
Publication of JP2020536107A5 publication Critical patent/JP2020536107A5/ja
Application granted granted Critical
Publication of JP7313345B2 publication Critical patent/JP7313345B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020519400A 2017-10-05 2018-10-05 デング熱に対するブースターワクチン接種のための組成物 Active JP7313345B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762568525P 2017-10-05 2017-10-05
US62/568,525 2017-10-05
PCT/IB2018/001219 WO2019069130A1 (en) 2017-10-05 2018-10-05 COMPOSITIONS FOR RECALL VACCINATION AGAINST DENGUE

Publications (3)

Publication Number Publication Date
JP2020536107A JP2020536107A (ja) 2020-12-10
JP2020536107A5 true JP2020536107A5 (enExample) 2021-11-11
JP7313345B2 JP7313345B2 (ja) 2023-07-24

Family

ID=64184125

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020519400A Active JP7313345B2 (ja) 2017-10-05 2018-10-05 デング熱に対するブースターワクチン接種のための組成物

Country Status (6)

Country Link
US (2) US11690903B2 (enExample)
EP (1) EP3691681A1 (enExample)
JP (1) JP7313345B2 (enExample)
AU (1) AU2018346724B2 (enExample)
SG (1) SG11202002933TA (enExample)
WO (1) WO2019069130A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11690903B2 (en) * 2017-10-05 2023-07-04 Sanofi Pasteur Compositions for booster vaccination against dengue
WO2022123470A1 (en) * 2020-12-10 2022-06-16 Reagene Biosciences Pvt. Ltd. Saliva based diagnostic assays for detection of sarscov2 receptor binding domain (rbd) neutralizing antibodies

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996040933A1 (en) 1995-06-07 1996-12-19 The Government Of The United States Of America, Represented By The Secretary Department Of Health And Human Services Infectious dengue 2 virus pdk-53 as quadravalent vaccine
US6962708B1 (en) 1997-02-28 2005-11-08 Acambis, Inc. Chimeric flavivirus vaccines
IL131600A0 (en) 1997-02-28 2001-01-28 Ora Vax Inc Chimeric flavivirus vaccines
US7227011B2 (en) 1998-06-04 2007-06-05 United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Nucleic acid vaccines for prevention of flavivirus infection
JP2002540170A (ja) 1999-03-26 2002-11-26 ウォルター リード アーミー インスティテュート オブ リサーチ 弱毒化デング熱２型ウイルスワクチン
EP1165130A2 (en) 1999-03-26 2002-01-02 Walter Reed Army Institute of Research Attenuated dengue-3 virus vaccine
JP2002540171A (ja) 1999-03-26 2002-11-26 ウォルター リード アーミー インスティテュート オブ リサーチ 弱毒化デング熱４型ウイルスワクチン
WO2000057908A2 (en) 1999-03-26 2000-10-05 Walter Reed Army Institute Of Research, Department Of The Army Attenuated dengue-1 virus vaccine
WO2001039802A1 (en) 1999-12-01 2001-06-07 Oravax, Inc. Chimeric flavivirus vaccines
WO2001060847A2 (en) 2000-02-16 2001-08-23 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Avirulent, immunogenic flavivirus chimeras
DK1159968T3 (da) 2000-05-30 2009-02-23 Univ Mahidol Attenuerede stammer af Dengue-virus og deres anvendelse i en vaccinesammensætning
AT410634B (de) 2001-02-21 2003-06-25 Franz X Dr Heinz Attenuierte lebendimpfstoffe
EP2292802B1 (en) 2001-05-22 2015-01-14 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Development of mutations useful for attenuating dengue viruses and chimeric dengue viruses
AU2002322026B2 (en) 2001-06-01 2008-03-13 Acambis Inc. Chimeric flavivirus vectors
US20050002968A1 (en) 2002-01-15 2005-01-06 Monath Thomas P. Flavivirus vaccines
KR101074175B1 (ko) 2002-01-15 2011-10-14 사노피 파스테르 바이오로직스 씨오 플라비바이러스 백신
WO2003101397A2 (en) 2002-05-31 2003-12-11 Acambis, Inc. Tetravalent dengue vaccines
KR20080018271A (ko) 2005-06-17 2008-02-27 사노피 파스퇴르 약독화된 뎅기 혈청형 2 균주
KR101536612B1 (ko) 2005-06-17 2015-07-14 사노피 파스퇴르 약독화된 뎅기 혈청형 1 균주
BRPI0614265A2 (pt) 2005-08-10 2011-03-22 Acambis Inc uso de uma vacina do vìrus da febre amarela e de uma vacina de flavivìrus quimérico e kit contendo referidas vacinas
EP1951865A4 (en) 2005-11-21 2010-06-23 Sanofi Pasteur Ltd STABILIZING FORMULATIONS FOR RECOMBINANT VIRUSES
CU23586A1 (es) 2005-11-22 2010-10-30 Ct Ingenieria Genetica Biotech Métodos y proteínas para el tratamiento profiláctico y/o terapéutico de los cuatro serotipos del virus de dengue y otros flavivirus
US7968102B2 (en) 2006-01-13 2011-06-28 Sanofi Pasteur S.A. Dengue chimeric viruses
FR2903605A1 (fr) 2006-07-12 2008-01-18 Sanofi Pasteur Sa Methode d'immunisation contre les quatres serotypes de la dengue
FR2906724B1 (fr) 2006-10-04 2009-03-20 Sanofi Pasteur Sa Methode d'immunisation contre les 4 serotypes de la dengue.
FR2909286B1 (fr) 2006-12-01 2012-06-08 Sanofi Pasteur Methode d'immunisation contre les 4 serotypes de la dengue
CA2676775A1 (en) 2007-01-31 2008-09-25 Sanofi Pasteur Biologics Co. Flavivirus vaccine vector against influenza virus
BRPI0913012B1 (pt) 2008-04-30 2021-12-14 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Quimera de ácido nucleico, métodos para detectar um anticorpo do vírus da dengue em uma amostra de um paciente, e para produzir partículas virais que expressam proteínas prm e e do vírus da dengue, uso de vírus codificado pela quimera e flavivírus ou partícula viral quiméricos
EP2143440A1 (fr) 2008-07-09 2010-01-13 Sanofi Pasteur Agent stabilisant et composition vaccinale comprenant un ou plusieurs flavivirus vivants atténués
US8968996B2 (en) 2009-06-01 2015-03-03 Takeda Vaccines, Inc. Compositions and methods for rapid immunization against dengue virus
CN102573891B (zh) 2009-07-29 2016-06-01 贝恩德·赫尔穆特·阿达姆·雷姆 聚合物微粒及其用途
EP2353609A1 (en) 2010-02-04 2011-08-10 Sanofi Pasteur Immunization compositions and methods
GB201007531D0 (en) 2010-05-05 2010-06-23 Imp Innovations Ltd Composition
CN102906266A (zh) 2010-05-21 2013-01-30 高等教育联邦系统-匹兹堡大学 登革病毒通用序列及其使用方法
WO2012051491A1 (en) 2010-10-14 2012-04-19 The United States Of America, As Represented By The Secretary National Institutes Of Health Compositions and methods for controlling neurotropic viral pathogenesis by micro-rna targeting
AU2013295014B2 (en) 2012-07-24 2018-01-18 Sanofi Pasteur Vaccine compositions
EP2877207A1 (en) 2012-07-24 2015-06-03 Sanofi Pasteur Vaccine compositions for prevention against dengue virus infection
US10518409B2 (en) * 2014-09-02 2019-12-31 Mark Oleynik Robotic manipulation methods and systems for executing a domain-specific application in an instrumented environment with electronic minimanipulation libraries
TWI852899B (zh) 2014-09-02 2024-08-21 法商賽諾菲巴斯德公司 疫苗組合物
WO2017005654A1 (en) 2015-07-03 2017-01-12 Sanofi Pasteur Concomitant dengue, diphtheria, tetanus, whooping cough (pertussis), polio, and haemophilus influenzae type b vaccination.
WO2017005652A1 (en) 2015-07-03 2017-01-12 Sanofi Pasteur Concomitant dengue and yellow fever vaccination
US11690903B2 (en) * 2017-10-05 2023-07-04 Sanofi Pasteur Compositions for booster vaccination against dengue

Similar Documents

Publication Publication Date Title
Chen et al. Yeast-expressed SARS-CoV recombinant receptor-binding domain (RBD219-N1) formulated with aluminum hydroxide induces protective immunity and reduces immune enhancement
Cai et al. A combination vaccine comprising of inactivated enterovirus 71 and coxsackievirus A16 elicits balanced protective immunity against both viruses
Minor Live attenuated vaccines: Historical successes and current challenges
Foo et al. Passive protection against lethal enterovirus 71 infection in newborn mice by neutralizing antibodies elicited by a synthetic peptide
Ikegami et al. Rift valley fever vaccines
Simmons et al. Protection against dengue virus by non-replicating and live attenuated vaccines used together in a prime boost vaccination strategy
Wang et al. Inactivated rotavirus vaccine induces protective immunity in gnotobiotic piglets
Zhou et al. Immunogenicity, safety, and protective efficacy of an inactivated SARS-associated coronavirus vaccine in rhesus monkeys
JP2019151636A5 (enExample)
Bröker et al. After a tick bite in a tick-borne encephalitis virus endemic area: current positions about post-exposure treatment
Zhang et al. Characterization of an inactivated whole-virus bivalent vaccine that induces balanced protective immunity against coxsackievirus A6 and A10 in mice
Baehner et al. Vaccines against norovirus: state of the art trials in children and adults
Patil et al. Neutralizing antibody responses to foot-and-mouth disease quadrivalent (type O, A, C and Asia 1) vaccines in growing calves with pre-existing maternal antibodies
JP2017526689A5 (enExample)
Terhuja et al. Comparative efficacy of virus like particle (VLP) vaccine of foot-and-mouth-disease virus (FMDV) type O adjuvanted with poly I: C or CpG in guinea pigs
Liu et al. Towards broadly protective polyvalent vaccines against hand, foot and mouth disease
CN113329767B (zh) 肠道病毒对vero细胞的适应及其疫苗制剂
Martinelle et al. Assessment of cross-protection induced by a bluetongue virus (BTV) serotype 8 vaccine towards other BTV serotypes in experimental conditions
Calvo-Pinilla et al. The immunogenicity of recombinant vaccines based on modified Vaccinia Ankara (MVA) viruses expressing African horse sickness virus VP2 antigens depends on the levels of expressed VP2 protein delivered to the host
Abente et al. Alphavirus-vectored hemagglutinin subunit vaccine provides partial protection against heterologous challenge in pigs
De Vleeschauwer et al. A canine adenovirus type 2 vaccine vector confers protection against foot-and-mouth disease in guinea pigs
Phillpotts et al. Monoclonal antibody protects mice against infection and disease when given either before or up to 24 h after airborne challenge with virulent Venezuelan equine encephalitis virus
Moreno et al. Recombinant Rift Valley fever viruses encoding bluetongue virus (BTV) antigens: Immunity and efficacy studies upon a BTV-4 challenge
Díaz et al. Comparison of different vaccination schedules for sustaining the immune response against porcine reproductive and respiratory syndrome virus
Zhang et al. Hexon-modified recombinant E1-deleted adenoviral vectors as bivalent vaccine carriers for Coxsackievirus A16 and Enterovirus 71